BioMed Research International / 2016 / Article / Tab 1

Review Article

Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Table 1

Studies exploring risk of lymphomas in patients with RA, SLE, Sjögren’s syndrome, inflammatory arthritis, and spondyloarthropathies.

Author YearCountryDiseasePopulation ()VariantRR/SIR/OR (CI)

Thomas et al. [11]2000ScotlandRA17/26,623
10/26,623
HD (SIR)
NHL
3.85 (2.2, 6.2)
2.13 (1.7, 2.6)
Mariette et al. [12] (TNFI) 2011UKRA18/30,000NHL1.07 (0.6, 1.7)
Ekström et al. [13]2003SwedenRA77/76,527
18/30,000
HD
NHL
3.06 (2.4, 3.8)
1.89 (1.7, 2.1)
Abásolo et al. [14] 2008Southern EuropeRA3/789NHL5.4 (1.1, 15.7)
Wolfe and Michaud [15] 2004USARA4/13,869
42/13,869
HD
NHL
3.0 (1.3, 6.8)
1.7 (1.3, 2.2)
Hemminki et al. [16]2008SwedenRA35/42,262
280/42,262
HD
NHL
4.05 (2.8, 5.6)
2.34 (2.1, 2.6)
Anderson et al. [17]2009USARA1157 cases/3289 controlsNHLOR 1.2 (1.1–1.3)
Askling et al. [18]2009SwedenRA26/26,981HD2.7 (1.8–4.1)
Parikh-Patel et al. [19]2009USARA325/84,475NHL - Men,
women
2.1 (1.7, 2.5)
1.4 (1.2, 1.6)
Hellgren et al. [20]2010SwedenRA19 cases/53 controlsHDOR 1.8 (1.0–3.0)
Chen et al. [21] 2010TaiwanRA1/23,644
59/23,644
HD
NHL
1.76 (1.5, 2.2)
3.54 (3.45, 3.63)
Mercer et al. [22]2013UKRA16/3771NHL3.12 (1.8, 5.1)
Dreyer et al. [23]2013DenmarkRA5/3812NHL2.27 (0.9, 5.5)
Anderson et al. [17]2009USASS142 cases/255 controlsNHL1.9 (1.5–2.3)
Zhang et al. [24]2010ChinaSS8/1320NHL48.1 (20.7–94.8)
Solans-Laqué et al. [25]2011SpainSS11/244NHL15.6 (8.7–28.2)
Weng et al. [26]2012TaiwanSS277/7852NHL - Men
NHL- Women
3.1 (0.6–9.0)
7.1 (4.2–10.3)
Johnsen et al. [27]2013NorwaySS7/443NHL9 (7.1–26.3)
Liang et al. [28] 2014Meta-analysisSS14 studiesLymphomas13.8 (8.5–19.0)
Feltelius et al. [29]2003SwedenAS12/6621Lymphomas1.3 (0.9–1.9)
Shibata et al. [30]2004JapanASNA/3262Lymphomas2.8 (1.4–5.6)
Becker et al. [31]2005GermanyAS710 cases/controlsLymphomas3.0 (0.1–29)
Askling et al. [32]2006SwedenAS50,615 cases/92,928 controlsLymphomas1.0 (0.6–1.7)
Mellemkjaer et al. [33]2008DenmarkAS25,941 cases/58,551 controlsLymphomas1.1 (0.6–1.8)
Anderson et al. [17]2009USAAS33,721 cases/122,531 controlsLymphomas1.1 (0.7–1.5)
Rohekar et al. [34]2008CanadaPsANA/665Lymphomas0.7 (0.3–1.8)
Gross et al. [35] 2014USAPsA3/2977Lymphomas0.4 (0.1–1.2)
Nived et al. [36]2001SwedenSLE2/116NHL11.63 (1.40, 42.0)
Cibere et al. [37]2001CanadaSLE4/297NHL7 (1.9, 8)
Björnådal et al. [38]2002SwedenSLE32/5715NHL2.86 (1.96, 4.04)
Tarr et al. [39]2007HungarySLE2/860NHL3.50 (0.4, 12.5)
Parikh-Patel et al. [40]2008USASLE96/30478NHL2.74 (2.22, 3.34)
Anderson et al. [17]2009USASLE129 cases/285 controlsNHL (OR)1.5 (1.2–1.9)
Kang et al. [41]2010KoreaSLE3/914NHL15.4 (2.9–37.7)
Chen et al. [21]2010TaiwanSLENA/11763Lymphomas7.3 (7.0–7.6)
Dreyer et al. [42]2011DenmarkSLE4/576NHL5.0 (1.9–13.3)
Bernatsky et al. [43]2013ScotlandSLE76/16409NHL
HL
4.4 (3.5–5.5)
2.3 (0.9–4.7)
Hill et al. [44] 2001Sweden, Denmark, and FinlandDermatomyositisNA/618NHL3.6 (1.2, 11.1)
Stockton et al. [45]2001ScotlandDermatomyositis2/50
1/50
NHL
HL
13.3 (1.6, 48)
28.4 (0.7, 157.9)
Hill et al. [44] 2001Sweden, Denmark, and FinlandPolymyositisNA/914NHL3.7 (1.7–8.2)
Stockton et al. [45]2001ScotlandPolymyositis2/40
2/40
NHL
HL
5 (0.6, 18.1)
31 (3.8, 112)

RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; AS: ankylosing spondylitis; SS: Sjögren’s syndrome; PsA: psoriatic arthritis; RR: relative risk; SIR: standardized incidence ratio; OR: odds ratio; CI: confidence interval; : number of cases of lymphoma; : study population; NA: not available.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.